Clinical Trials Logo

Gastrinoma clinical trials

View clinical trials related to Gastrinoma.

Filter by:

NCT ID: NCT04915144 Withdrawn - Clinical trials for Neuroendocrine Tumors

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Start date: January 15, 2023
Phase: Phase 2
Study type: Interventional

This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT. Subjects will be randomized to either receive personalized or standard PRRT. Personalized PRRT will be determined based on dosimetry calculations after the first cycle. In addition comparisons, will be made with progression-free survival, serial CT imaging, ctDNA, and quality of life questionnaires. Subjects will be followed for 5 years or until they have progression and are switched to another systemic treatment (not including treatment with somatostatin analogues).

NCT ID: NCT03583528 Recruiting - Neuroblastoma Clinical Trials

DOTATOC PET/CT for Imaging NET Patients

Start date: July 11, 2018
Phase:
Study type: Observational

Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventional imaging are used to detect NETs. This study proposes 68Gallium(68Ga)-DOTATOC positron emission tomography/computed tomography (PET/CT) is superior to current imaging techniques. The goal is to evaluate the safety and sensitivity of 68Ga-DOTATOC PET/CT at detecting NETs and other tumors with over-expression of somatostatin receptors.

NCT ID: NCT03147768 Completed - Clinical trials for Pancreatic Neoplasms

Laser Tissue Welding - Distal Pancreatectomy Sealing Study

LTW
Start date: January 1, 2018
Phase: Phase 1
Study type: Interventional

The laser tissue welding device is intended for use in patients requiring sealing of the pancreas after partial pancreatectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure. The hypothesis is that the laser tissue welding device is safe and effective in sealing the pancreas, thereby decreasing the blood loss (operative and post-operative), and pancreatic juice leakage for patients when the Laser Tissue Welding device is used after pancreatic resection.

NCT ID: NCT02831179 Withdrawn - Clinical trials for Merkel Cell Carcinoma

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Start date: December 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually cannot be cured or controlled with treatment, has returned after a period of improvement, and cannot be removed by surgery. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT02454075 Terminated - Clinical trials for Zollinger-Ellison Syndrome

YF476 and Type II Gastric Carcinoids

Start date: April 11, 2011
Phase: Phase 2
Study type: Interventional

This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison syndrome.

NCT ID: NCT02273752 Terminated - Clinical trials for Stage IV Breast Cancer

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Start date: November 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well real-time pharmacokinetic therapeutic drug monitoring works in preventing stomatitis from developing in patients with hormone receptor positive breast cancer, pancreatic neuroendocrine tumors, or kidney cancer that are receiving a type of cancer drug called everolimus. Stomatitis is a common side effect of everolimus that causes inflammation of the mouth, with or without oral ulcers, and frequently leads to patients discontinuing the medication. Monitoring the blood levels of everolimus and making adjustments in a patient's dose may be able to decrease the incidence of stomatitis, while maintaining the effectiveness of everolimus to treat the cancer.

NCT ID: NCT02259725 Completed - Insulinoma Clinical Trials

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Start date: August 16, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02153398 Completed - Clinical trials for Zollinger-Ellison Syndrome

A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases

Start date: June 2014
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old who either have a diagnosis of or are suspected to have gastric ulcer (GU), duodenal ulcer (DU), anastomotic ulcer (AU), non-erosive reflux esophagitis disease (NERD), reflux esophagitis (RE) or Zollinger-Ellison syndrome.

NCT ID: NCT02108782 Withdrawn - Insulinoma Clinical Trials

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Start date: October 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well dovitinib lactate works in treating patients with pancreatic neuroendocrine tumors. Dovitinib lactate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02031536 Terminated - Liver Metastases Clinical Trials

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Start date: April 10, 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well everolimus works in treating patients with pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving everolimus after surgery may kill any tumors cells that remain.